Atractylenolide III Enhances the Anti-Neoplastic Efficacy of Docetaxel in Gastric Cancer Cell by Inhibiting Fibroblast Growth Factor Receptors 1, -2, and -4 Expression

2019 ◽  
Vol 38 (3) ◽  
pp. 217-227 ◽  
Author(s):  
Yanxia Ji ◽  
Zhenqiao Kang ◽  
Ning Kang ◽  
Yanzheng Zhao ◽  
Qing Guo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cancer Cell ◽  
Gastric Cancer Cell ◽  
Growth Factor Receptors ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors ◽  
Atractylenolide Iii

Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer

2000 ◽  
Vol 126 (9) ◽  
pp. 519-528 ◽  
Author(s):  
Eun-Young Shin ◽  
Bin-Ho Lee ◽  
Jong-Ho Yang ◽  
Kyeong-Sun Shin ◽  
Geon-Kook Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Growth Factor Receptors ◽  
Human Gastric Cancer ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors

scholarly journals Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Mikito Inokuchi ◽  
Yoshitaka Fujimori ◽  
Sho Otsuki ◽  
Yuya Sato ◽  
Masatoshi Nakagawa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Signaling Pathways ◽  
Fibroblast Growth Factor ◽  
Growth Factor Receptor ◽  
Growth Factor Receptors ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors ◽  
Genomic Amplification

Chemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal antibodies targeting human epidermal growth factor receptor 2 (HER2) have become standard therapy for HER2-positive GC. An inhibitor of vascular endothelial growth factor receptor 2 or MET has also produced promising results in patients with GC. Fibroblast growth factor receptors (FGFR) play key roles in tumor growth via activated signaling pathways in GC. Genomic amplification of FGFR2 leads to the aberrant activation found in GC tumors and is related to survival in patients with GC. This review discusses the clinical relevance of FGFR in GC and examines FGFR as a potential therapeutic target in patients with GC. Preclinical studies in animal models suggest that multitargeted tyrosine kinase inhibitors (TKIs), including FGFR inhibitor, suppress tumor cell proliferation and delay tumor progression. Several TKIs are now being evaluated in clinical trials as treatment for metastatic or unresectable GC harboring FGFR2 amplification.

scholarly journals Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer

2014 ◽  
Vol 2 (4) ◽  
pp. 509-517 ◽  
Author(s):  
HIDEAKI MURASE ◽  
MIKITO INOKUCHI ◽  
YOKO TAKAGI ◽  
KEIJI KATO ◽  
KAZUYUKI KOJIMA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Prognostic Significance ◽  
Growth Factor Receptors ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors

scholarly journals Targeting fibroblast growth factor receptors to combat aggressive ependymoma

2021 ◽  
Author(s):  
Daniela Lötsch ◽  
Dominik Kirchhofer ◽  
Bernhard Englinger ◽  
Li Jiang ◽  
Konstantin Okonechnikov ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Molecular Mechanisms ◽  
Radial Glia ◽  
Growth Factor Receptors ◽  
Dominant Negative ◽  
Mrna Levels ◽  
Fibroblast Growth ◽  
Cell Models ◽  
Fibroblast Growth Factor Receptors

AbstractEpendymomas (EPN) are central nervous system tumors comprising both aggressive and more benign molecular subtypes. However, therapy of the high-risk subtypes posterior fossa group A (PF-A) and supratentorial RELA-fusion positive (ST-RELA) is limited to gross total resection and radiotherapy, as effective systemic treatment concepts are still lacking. We have recently described fibroblast growth factor receptors 1 and 3 (FGFR1/FGFR3) as oncogenic drivers of EPN. However, the underlying molecular mechanisms and their potential as therapeutic targets have not yet been investigated in detail. Making use of transcriptomic data across 467 EPN tissues, we found that FGFR1 and FGFR3 were both widely expressed across all molecular groups. FGFR3 mRNA levels were enriched in ST-RELA showing the highest expression among EPN as well as other brain tumors. We further identified high expression levels of fibroblast growth factor 1 and 2 (FGF1, FGF2) across all EPN subtypes while FGF9 was elevated in ST-EPN. Interrogation of our EPN single-cell RNA-sequencing data revealed that FGFR3 was further enriched in cycling and progenitor-like cell populations. Corroboratively, we found FGFR3 to be predominantly expressed in radial glia cells in both mouse embryonal and human brain datasets. Moreover, we detected alternative splicing of the FGFR1/3-IIIc variant, which is known to enhance ligand affinity and FGFR signaling. Dominant-negative interruption of FGFR1/3 activation in PF-A and ST-RELA cell models demonstrated inhibition of key oncogenic pathways leading to reduced cell growth and stem cell characteristics. To explore the feasibility of therapeutically targeting FGFR, we tested a panel of FGFR inhibitors in 12 patient-derived EPN cell models revealing sensitivity in the low-micromolar to nano-molar range. Finally, we gain the first clinical evidence for the activity of the FGFR inhibitor nintedanib in the treatment of a patient with recurrent ST-RELA. Together, these preclinical and clinical data suggest FGFR inhibition as a novel and feasible approach to combat aggressive EPN.

scholarly journals Differential Roles of Fibroblast Growth Factor Receptors (FGFR) 1, 2 and 3 in the Regulation of S115 Breast Cancer Cell Growth

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e49970 ◽  
Author(s):  
Kati M. Tarkkonen ◽  
Emeli M. Nilsson ◽  
Tiina E. Kähkönen ◽  
Julien H. Dey ◽  
Jari E. Heikkilä ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cell Growth ◽  
Fibroblast Growth Factor ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors ◽  
Cancer Cell Growth ◽  
Breast Cancer Cell Growth

Semirational design of a potent, artificial agonist of fibroblast growth factor receptors

10.1038/70746 ◽  
1999 ◽  
Vol 17 (12) ◽  
pp. 1199-1204 ◽  
Author(s):  
Marcus D. Ballinger ◽  
Venkatakrishna Shyamala ◽  
Louise D. Forrest ◽  
Maja Deuter-Reinhard ◽  
Laura V. Doyle ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Growth Factor Receptors ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Receptors
Sign in / Sign up

Export Citation Format

Share Document